Hyderabad, May 19, 2015
Shares of Dr Reddy’s Labs jumped nearly 3 per cent to hit intraday high of Rs 3,591.80 after the company on Friday said that it has launched a drug for treatment of post-stroke patients.
Dr Reddy’s Labs has launched Somazina in the Indian markets. the drug’s is innovator brand is Citicoline. Dr. Reddy’s has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India.
Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.
The stock reacted positively to this news. The stock closed 3.6 per cent at Rs 3,622. Business Line
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…